Trudhesa® (dihydroergotamine mesylate) nasal spray | Official Healthcare Professional (HCP) Site | Impel NeuroPharma®
Ready to deliver relief3,4
Trudhesa® is the only acute treatment for migraine that uses advanced Precision Olfactory Delivery (POD®) technology to consistently deliver dihydroergotamine mesylate (DHE) to the vascular-rich upper nasal space, for rapid relief and sustained pain freedom, even when taken late in a migraine attack.2-4
Exploratory end points and post hoc analyses of patient-reported efficacy data for some patients showed the following results4*:
Pain relief in as fast as 15 minutes4
Pain freedom lasted 2 days with 1 dose4
Results delivered time after time3
Even late in an attack
Pain freedom on their terms, even when taken late into a migraine attack4-6
*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa.4
How many migraine days per month are your patients STILL having?
Create a comprehensive treatment plan with Trudhesa. Learn how Trudhesa delivers relief by sending medication to the upper nasal space and how you can prescribe Trudhesa as an add-on for your patients already using a gepant.2,3
The Trudhesa Patient
The Trudhesa Patient
References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214-1226. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Pharmaceuticals. 2020.